HTTP 200 OK
Allow: GET, PUT, PATCH, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"resource_uri": "https://fragdenstaat.de/api/v1/message/587040/",
"id": 587040,
"url": "https://fragdenstaat.de/anfrage/korrespondenz-mit-deutschen-behorden-zum-tlw-impfstopp-der-astrazeneca-impfung-am-30032021/#nachricht-587040",
"request": "https://fragdenstaat.de/api/v1/request/217097/",
"sent": true,
"is_response": true,
"is_postal": false,
"is_draft": false,
"kind": "email",
"is_escalation": false,
"content_hidden": false,
"sender_public_body": "https://fragdenstaat.de/api/v1/publicbody/16035/",
"recipient_public_body": null,
"status": "awaiting_response",
"timestamp": "2021-04-13T17:20:08+02:00",
"registered_mail_date": null,
"redacted": false,
"not_publishable": false,
"attachments": [],
"subject": "ASK-81593 Korrespondenz mit deutschen Behörden zum tlw. Impfstopp der AstraZeneca-Impfung am 30.03.2021 [#217097]",
"content": "Dear Requester,\n\nThank you for contacting us on 6 April 2021.\n\nWe hereby acknowledge receipt of your application for access to documents, which was registered on the same day under reference number ASK-81593.\n\nWe will deal with your request as soon as possible and in accordance with the principles and limits established in Regulation (EC) 1049/2001 regarding public access to European Parliament, Council and Commission documents (the Regulation), as applicable to the EMA pursuant to Article 73 of Regulation (EC) 726/2004.\n\nIn accordance with the Regulation, you will receive a reply via a secure Eudralink within 15 working days. The Agency may extend this period by a further 15 working days in exceptional circumstances in accordance with the Regulation.\n\nPlease note that the European Medicines Agency is currently operating within a business continuity plan to ensure operational continuity following its relocation to Amsterdam and during the continuing COVID-19 pandemic. Whilst every effort is being made to process your request as soon as possible, you should be aware that due to these exceptional circumstances, we may have to extend the deadline as outlined above. Should such an extension be applied by the Agency, you will be informed at the time.\n\nIn case this email becomes publicly available, please redact personal data such as the first name and surname of the sender, e-mail address as well as any other personal data, as relevant. The Agency considers this information to be protected personal data in the meaning of Article 3(1) of Regulation (EU) No 2018/1725 and Article 4(1) of the General Data Protection Regulation EU 2016/679. Personal data is information that permits to identify a natural person.\n\nKind regards,",
"redacted_subject": [
[
false,
"ASK-81593 Korrespondenz mit deutschen Behörden zum tlw. Impfstopp der AstraZeneca-Impfung am 30.03.2021 [#217097]"
]
],
"redacted_content": [
[
false,
"Dear Requester,\n\nThank you for contacting us on 6 April 2021.\n\nWe hereby acknowledge receipt of your application for access to documents, which was registered on the same day under reference number ASK-81593.\n\nWe will deal with your request as soon as possible and in accordance with the principles and limits established in Regulation (EC) 1049/2001 regarding public access to European Parliament, Council and Commission documents (the Regulation), as applicable to the EMA pursuant to Article 73 of Regulation (EC) 726/2004.\n\nIn accordance with the Regulation, you will receive a reply via a secure Eudralink within 15 working days. The Agency may extend this period by a further 15 working days in exceptional circumstances in accordance with the Regulation.\n\nPlease note that the European Medicines Agency is currently operating within a business continuity plan to ensure operational continuity following its relocation to Amsterdam and during the continuing COVID-19 pandemic. Whilst every effort is being made to process your request as soon as possible, you should be aware that due to these exceptional circumstances, we may have to extend the deadline as outlined above. Should such an extension be applied by the Agency, you will be informed at the time.\n\nIn case this email becomes publicly available, please redact personal data such as the first name and surname of the sender, e-mail address as well as any other personal data, as relevant. The Agency considers this information to be protected personal data in the meaning of Article 3(1) of Regulation (EU) No 2018/1725 and Article 4(1) of the General Data Protection Regulation EU 2016/679. Personal data is information that permits to identify a natural person.\n\nKind regards,"
]
],
"sender": "Europäische Arzneimittel-Agentur",
"status_name": "Warte auf Antwort",
"last_modified_at": "2024-01-03T16:02:23.118447+01:00"
}